FACTORS AFFECTING USE OF MEDICATION TO TREAT ALCOHOLISM

影响使用药物治疗酗酒的因素

• 批准号: 6371531
• 负责人: TAMI L MARK
• 金额: $ 12.88万
• 依托单位: TRUVEN HEALTH ANALYTICS, INC.
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-07-01 至 2003-10-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6371531
• 关键词: alcoholism /alcohol abuse chemotherapy; behavioral /social science research tag; clinical research; decision making; health care service evaluation; health services research tag; human subject; naltrexone; physicians

In January 1995, naltrexone, marketed under the name REVIATM became the first medication approved by the Food and Drug Administration for alcoholism treatment in almost 50 years. The ifficacy of naltrexone, as an adjunct to therapy, in decreasing the mean number of drinking days per week, the frequency of relapse, and subjective craving for alcohol with few side effects has been shown in double blind randomized clinical trials. Despite the evidence of its efficacy, reports of its use indicate that it is not as widespread as might be expected. Total prescription of Revia in 1998 (including prescription for narcotic treatment) were 13,000 per month, only slightly more than the number of prescriptions in 1996. The 1992 National Longitudinal Alcohol Epidemiologic Survey estimated that 13.7 million adults met the criteria for alcohol abuse and alcohol dependence during the year preceding the interview (Grant, 1995). The one-day census of specialty substance abuse providers (NDATUS) indicates that in 1996, there were 677,000 clients in treatment for alcoholism. This figure excludes persons receiving treatment for alcoholism in institutions specializing in mental health care and in primary care settings. Thus, perhaps only 2 percent of persons receiving alcoholism treatment are being treated with naltrexone. Given the low utilization of naltrexone in the face of its apparent efficacy, it is critical to understand the barriers to the adoption of this important new pharmacological tool. The goal of this proposed research is to identify the factors that are influencing the use of naltrexone and to gain insight into its perceived efficacy among practitioners. Towards this end, the primarily aims of this study are: (1) to identify factors influencing use of naltrexone and their relative importance; (2) to determine whether other new medications to treat alcoholism are likely to face barriers to prescribing; (3) to identify methods that physicians used to overcome barriers to prescribing naltrexone; (4) to collect information on the types of patients being prescribed naltrexone and the circumstances under which it is being prescribed. We propose to collect this information through experts panels and a national survey of physicians specialized in treating substance abuse.

1995年1月，以Reviatm的名义销售的Naltrexone成为近50年来酒精中毒治疗的第一种药物。 纳曲酮作为治疗的辅助性，减少每周平均饮酒天数，复发的频率以及对酒精的主观渴望，而副作用很少，但在双盲盲随机临床试验中已显示出很少的副作用。尽管有其功效的证据，但其使用的报告表明，它并不像预期的那样普遍。 1998年的Revia总处方（包括用于麻醉剂的处方）每月13,000，仅略高于1996年的处方数量。1992年的全国纵向酒精流行病学调查估计，1370万成人符合访谈前一年中酒精滥用和酒精依赖的标准（Grant，1995年）。特殊药物滥用提供者（NDATUS）的为期一天的人口普查表明，1996年，有677,000名酒精中毒治疗的客户。 该数字不包括在专门从事精神保健和初级保健环境的机构中接受酒精中毒治疗的人。 因此，也许只有2％接受酒精中毒治疗的人接受了纳曲酮治疗。 鉴于面对明显的疗效，纳曲酮的利用率较低，因此必须了解采用这种重要的新药理工具的障碍至关重要。这项拟议的研究的目的是确定影响纳曲酮使用的因素，并深入了解其在从业者中的感知功效。 为此，这项研究的主要目的是：（1）确定影响使用纳曲酮及其相对重要性的因素； （2）确定其他新药物治疗酒精中毒是否可能面临开处方的障碍； （3）确定医生用来克服开处方纳曲酮的障碍的方法； （4）收集有关处方纳曲酮的患者类型及其处方情况的信息。 我们建议通过专家小组和专门治疗药物滥用的医师的全国医师调查收集这些信息。

项目成果

The costs of treating persons with depression and alcoholism compared with depression alone.

与单独治疗抑郁症相比，治疗抑郁症和酗酒患者的费用。

• DOI: 10.1176/appi.ps.54.8.1095
• 发表时间: 2003
• 期刊: Psychiatric services (Washington, D.C.)
• 作者: Mark,TamiL